BINDING PEPTIDES I
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 5, 2014
app pub date -
Dec 5, 2011
filing date -
Dec 3, 2010
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A modified igNAR peptide sequence derived from a wild-type igNAR peptide sequence is diversified by mutating the amino acid sequence at 50% or more of the amino acids in the CDR3 loop region and optionally at 50% or more of the amino acids in the CDR3 loop region. The modified igNAR peptide may have the sequence of SEQ ID NO: 8, 10 or 50 to 85. The modified igNAR peptides have binding activity against albumin protein sequences, such as human serum albumin. These modified igNAR peptides may have utility in extending the in vivo half-life of biological molecules e.g. therapeutic agents, and so may be used in medicine.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully